TL;DR
This systematic review and meta-analysis consolidates evidence from 61 animal studies, revealing that plant-derived extracts and compounds show significant promise in combating Helicobacter pylori-associated gastritis (HAG). These natural agents demonstrate both anti-H. pylori and anti-inflammatory effects by modulating key cellular pathways, offering a potential avenue for developing novel therapeutic strategies against this widespread condition.
What Problem Does This Paper Address?
Helicobacter pylori infection is a major global health concern, leading to chronic gastritis (HAG) and increasing the risk of peptic ulcers, gastric cancer, and other serious gastrointestinal diseases. Current eradication therapies, primarily proton pump inhibitor (PPI)-based triple therapies, are facing growing challenges due to rising antibiotic resistance, leading to treatment failures and recurrent infections. This situation creates an urgent need for alternative or complementary therapeutic approaches. The paper addresses this by systematically reviewing and analyzing the efficacy of plant-derived extracts and compounds as potential treatments for HAG, focusing on their anti-H. pylori and anti-inflammatory activities in animal models.
Methods
This study employed a rigorous systematic review and meta-analysis methodology, adhering to the PRISMA statement and registered with PROSPERO. A comprehensive literature search was conducted across multiple databases (PubMed, Scopus, Web of Science, Embase, CNKI, VIP, Wanfang, SinoMed) up to November 2023. Inclusion criteria focused on studies using animal models of HAG treated with plant-derived extracts or compounds, with comparative control groups and outcomes related to anti-H. pylori and anti-inflammatory effects. The SYRCLE risk of bias tool was used to assess the quality of included studies. Meta-analyses were performed using Review Manager software to estimate the effects of interventions on anti-H. pylori and anti-inflammatory activities.
Datasets
The study did not introduce new datasets. Instead, it systematically collected and analyzed data from 61 published research articles that utilized various animal models (primarily mice and rats) to study H. pylori-associated gastritis.
Key Insights and Ideas
- Natural Compounds as a Promising Alternative: The review strongly suggests that plant-derived agents can effectively combat HAG, offering a potential solution to the growing problem of antibiotic resistance.
- Multi-Targeted Action: The identified plant extracts and compounds don't just target H. pylori directly; they also modulate crucial inflammatory and cellular pathways, indicating a holistic approach to managing the disease.
- Key Signaling Pathways Identified: The research highlights several critical signaling pathways (NF-κB, JAK/STAT3, MAPK, TLR4/MyD88, PI3K/AKT, NLRP3/Caspase-1, NRF2/HO-1) that are significantly influenced by these natural compounds, providing a mechanistic understanding of their therapeutic effects.
- Traditional Chinese Medicine (TCM) Relevance: The study underscores the rich history and potential of TCM in treating HAG, with many identified plants and compounds having established roles in traditional medicine.
- Focus on Early Stages: The findings emphasize the value of these phytomedicines in intervening at the early stages of HAG, potentially preventing the progression to more severe conditions like gastric atrophy, intestinal metaplasia, and ultimately, gastric cancer.
Key Results
- Anti-H. pylori Activity: Meta-analysis showed that plant extracts and compounds significantly reduced positive rates for the Campylobacter-Like Organism (CLO) test (RR=0.31, 95% CI 0.16 to 0.59) and the Rapid Urease Test (RUT) (RR=0.46, 95% CI 0.32 to 0.66).
- Anti-inflammatory Effects: Several plant-derived substances significantly decreased pro-inflammatory cytokine levels, including IL-1β (SMD = -2.32, 95% CI -3.66 to -0.97 for protein level; SMD = -1.15, 95% CI -1.69 to -0.60 for pg/ug) and TNF-α (SMD = -3.13, 95% CI -4.06 to -2.20 for pg/mL; SMD = -1.38, 95% CI -1.93 to -0.84 for pg/ug).
- Broad Efficacy: The review identified 61 studies involving 36 extracts and 37 compounds that improved HAG by inhibiting H. pylori infection, reducing inflammation, mitigating oxidative stress, and regulating apoptosis and proliferation.
- Promising Plant Families and Compound Classes: Asteraceae, Fabaceae, and Rosaceae were identified as the top three plant families, while Terpenoids, Alkaloids, Phenols, and Flavonoids were the most frequent compound classes showing promise.
Limitations and Future Work
The authors acknowledge several limitations:
- Study Quality: The quality of the included studies was rated as medium, with many studies exhibiting incomplete randomization methods and blinding information, which could impact the accuracy of the findings.
- Animal Models vs. Humans: All studies were conducted on animal models. While these models share physiological similarities with humans, the direct translation of these findings to human efficacy remains uncertain.
- Methodological Heterogeneity: Diverse methods used in animal models and variations in intervention administration, outcome indicators, and parameter units made comprehensive meta-analysis challenging.
Future Work: The authors strongly recommend further exploration of the application of these plant extracts and compounds in human clinical trials. They suggest prioritizing plants and compounds from the identified promising families and classes, and investigating the mechanisms of multiple components in established TCM formulas. Further research is needed to optimize dosages and co-administration strategies for enhanced clinical outcomes and novel drug development.
Summary updated